HAUSFELD-&-CO-LLP
22.2.2021 09:02:10 CET | Business Wire | Pressemeddelelse
Fra 12. til 16. juli 2021 vil Competition Appeal Tribunal (CAT) tage stilling til, hvorvidt det skal godkende en begæring om kollektivt søgsmål/gruppesøgsmål (FX Claim UK ) indbragt af Phillip Evans, repræsentant for gruppen og tidligere formand for undersøgelseskomitéen ved den britiske Competition and Markets Authority. Søgsmålet er rettet mod enheder, der indgår i følgende bankkoncerner: Barclays, Citibank, The Royal Bank of Scotland/NatWest, JPMorgan, UBS og MUFG Bank.
Hver af bankerne har indrømmet overtrædelser af EU's konkurrencelovgivning i forbindelse med spothandel med valuta. Phillip Evans’ foreslåede krav søger kompensation fra bankerne på vegne af foreslåede grupper af personer, som hævdes at have lidt tab som følge af bankernes deltagelse i de pågældende overtrædelser.
CAT har udstedt en bekendtgørelse vedrørende dette retsmøde, som kan findes her .
Phillip Evans har engageret Hausfeld & Co LLP, et førende advokatfirma inden for tvister og konflikter, til at føre sagen. Hausfeld & Co LLP’s amerikanske søsterselskab, Hausfeld LLP, er et af de førende advokatfirmaerne i et lignende kollektivt søgsmål i USA, der inddrev mere end 2,3 mia. USD til personer, som var blevet berørt af overtrædelser mht. valutahandel i USA.
Phillip Evans' begæring anmoder CAT om at godkende kravet som kvalificeret til at fortsætte som kollektivt søgsmål på vegne af berettigede enheder og enkeltpersoner samt at godkende, at Phillip Evans agerer som repræsentant for gruppen.
CAT behandler Phillip Evans' begæring samtidigt med en anden begæring om kollektivt søgsmål relateret til valutahandelskarteller, der er fremsat af Michael O’Higgins FX Class Representative Limited. Det betyder, at CAT skal afgøre, hvilken af repræsentanterne der er bedst egnet til at handle som repræsentant for gruppen. Dette er første gang, at CAT er blevet bedt om at afklare en tvist af denne type i relation til kollektive søgsmål.
Enhver person med interesse i de to begæringer (herunder foreslåede medlemmer af gruppen) kan gøre indsigelse mod en af eller begge begæringerne eller bemyndigelsen af en af eller begge foreslåede repræsentanter ved at kontakte CAT og angive deres grunde til at gøre indsigelse senest kl. 16.00 den 4. maj 2021. Disse personer kan også anmode om tilladelse til at fremsætte skriftlige og/eller mundtlige bemærkninger under retsmødet i juli ved at sende en ansøgning herom, understøttet med begrundelser, til domstolen senest kl. 16.00 den 4. maj 2021.
Phillip Evans udtaler: "Det er i gruppens medlemmers interesse, at spørgsmål om certificering og valg af repræsentant afgøres så hurtigt som muligt. Det glæder mig, at domstolen har besluttet at afholde retsmødet om certificeringen i juli 2021."
Med forbehold for eventuelle ændringer som følge af Covid-19-pandemien vil retsmødet finde sted i Competition Appeal Tribunal, Salisbury Square House, 8 Salisbury Square, London EC4Y 8AP. For oplysninger om, hvordan du deltager i domstolens behandling af de to begæringer ved at aflevere skriftlige bemærkninger eller for at ansøge om at blive hørt ved retsmødet i juli, skal du gå ind på www.fxclaimuk.com og læse CATs bekendtgørelse her .
Slut
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20210222005078/da/
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
SES Announces Extraordinary General Meeting of Shareholders15.5.2026 08:30:00 CEST | Press release
SES: Société Anonyme RCS Luxembourg B 81267 Notice is hereby given of the Extraordinary General Meeting of SES, Société Anonyme, to be held at the Company's registered office at Château de Betzdorf, L-6815 Betzdorf (the "Company"), Luxembourg, on Wednesday 17 June 2026 at 3:00 p.m. CET AGENDA Attendance list, quorum and adoption of the agenda Nomination of a secretary and of two scrutineers Cancellation of shares purchased in connection with the buy-back programme of 2 November 2023, as amended on 2 May 2024, in accordance therewith and pursuant thereto - Reduction of the share capital in accordance with article 450-5 of the law of 10 August 1915 on commercial companies, as amended, by forty-four million nine hundred ten thousand seven hundred eighty euro (EUR 44,910,780) through the cancellation of thirty-five million nine hundred and twenty-eight thousand six hundred and twenty-four (35,928,624) shares divided into (i) twenty-three million nine hundred and fifty-two thousand four hun
Experian Partners With ServiceNow to Scale Trusted Decisioning to Agentic AI15.5.2026 08:00:00 CEST | Press release
New global long‑term partnership embeds Experian’s Ascend capabilities directly into ServiceNow workflows, transforming client operations Experian, the global data and technology company, and ServiceNow (NYSE: NOW), the AI control tower for business reinvention, today unveil a new global multi-year partnership which harnesses the power of autonomous AI agents across platforms, helping businesses make faster and smarter decisions at scale. Through this partnership, autonomous AI agents can gain the ability to act faster, and more consistently, starting with employee onboarding, third-party risk management and model life cycle governance use cases. A major challenge for global organisations adopting agentic AI is achieving scale, with deployments often constrained by a lack of trusted data. In fact, industry research shows that data limitations are the primary barrier for eight in ten organisations. By connecting trusted intelligence directly into enterprise workflows, this partnership e
Meiji Seika Pharma: Positive Results from the Phase III Integral-1 Trial of Nacubactam, a Novel β-Lactamase Inhibitor, in Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis ― Published in The Lancet15.5.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (headquartered in Tokyo; President and Representative Director: Toshiaki Nagasato) today announced that the results of the Integral-1 study, one of two global Phase III clinical trials evaluating the efficacy and safety of its novel β-lactamase inhibitor nacubactam (development code: OP0595), have been published in The Lancet. The article is entitled “---Efficacy and safety of cefepime–nacubactam and aztreonam–nacubactam compared with imipenem–cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial” (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00596-9/fulltext) Integral-1 is a global, double-blind, randomized Phase III trial (jRCT2031230075) in patients with complicated urinary tract infection or acute uncomplicated pyelonephritis that compared the efficacy and safety of nacubactam co-administered with either cefepime or aztreonam versus imipenem-c
Boomi Teams up With Gong to Bring Revenue AI to Boomi Agentstudio14.5.2026 18:00:00 CEST | Press release
Gong's revenue AI is now natively available in the Boomi Enterprise Platform Boomi, the data activation company for AI, today announced a collaboration withGong, the leader in Revenue AI, to bring revenue signals captured in Gong natively into the Boomi Enterprise Platform. This collaboration enables enterprises to establish an active data foundation designed to transform customer conversations into coordinated, automated actions across systems and functions enterprise-wide with Boomi Agentstudio. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514443012/en/ Boomi Teams Up with Gong to Bring Revenue AI to Boomi Agentstudio Gong goes beyond capturing deal activity to surface real-time insights into risk, buyer intent, competitive dynamics, and key engagement signals. That intelligence moves from conversation to coordinated action, flowing across CRM, ERP, product, and operational systems with the governance and security tha
Xsolla and Skich Announce Strategic Partnership to Bring Merchant of Record Payments to an Alternative Mobile Game Marketplace14.5.2026 18:00:00 CEST | Press release
Partnership Enables Developers To Monetize Games On The Skich Store With Xsolla Handling Payments, Tax Compliance, And Commerce Infrastructure Xsolla, a leading global video game commerce company, today announced a strategic partnership with Skich, an alternative mobile game marketplace operating on iOS in the EU under Apple's Digital Markets Act provisions and on Android globally. Under the agreement, Xsolla will serve as Merchant of Record for in-app purchases and paid game sales distributed through the Skich Store. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514867730/en/ Graphic: Xsolla Skich serves as an alternative to traditional mobile storefronts, offering developers a way to reach players outside platform-controlled distribution channels. The partnership with Xsolla enables Skich to offer a fully compliant payment and commerce layer, with Xsolla managing payment processing, tax collection, refunds, and regulat
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum